Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$25.17 USD
-1.18 (-4.48%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $25.16 -0.01 (-0.04%) 6:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Akero Therapeutics, Inc. [AKRO]
Reports for Purchase
Showing records 101 - 108 ( 108 total )
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Let''s Dive Into FGF21 Biology With Dr. Arun Sanyal on Sept. 18 at 11am ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Join Our Doc Call Series on Drug Pricing
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
What Does It Take to Lift the Low NASH Sentiment?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 - Holding Well Through the Rough NASH Sentiment
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and $34 price target
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.